Immediate release tablet cores of insoluble drugs having sustained-release coating

• US 5,500,227 A
• Filed: 11/23/1993
• Issued: 03/19/1996
• Est. Priority Date: 11/23/1993
• Status: Expired due to Term

• Current Assignee: Euroceltique SA
• Original Assignee: Euroceltique SA
• Inventors: Oshlack, Benjamin, Chasin, Mark
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Spear, James M.
• Application Number:
  US08/156,460
• Time in Patent Office: 847 Days
• Field of Search: 424/479, 424/475, 424/480, 424/482, 424/476, 424/481
• US Class Current: 424/476
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

A controlled release tablet for oral administration is disclosed which has a tablet core including an insoluble therapeutically active agent having an aqueous solubility of less than or equal to about 5 mg/ml in a sufficient amount to render a therapeutic effect. The core provides rapid release of said therapeutically active agent upon exposure to aqueous solutions. The tablet core is coated with a controlled release coating permitting sustained release of said therapeutically active agent when said coated tablet is exposed to aqueous solutions.

Claims

1. A sustained release tablet for oral administration, comprising an immediate release tablet core including an insoluble therapeutically active agent having an aqueous solubility of less than or equal to about 5 mg/ml, said tablet core containing a sufficient amount of said therapeutically active agent to render a therapeutic effect, and

a film coating formed over said core, said film coating comprising a sufficient amount of a hydrophobic material selected from the group consisting of waxes, shellac, zein, fatty alcohols, hydrogenated vegetable oils, water insoluble celluloses, acrylic polymers and mixtures thereof to provide a sustained release of said therapeutically active agent sufficient to provide a duration of effect from about 8 to about 24 hours when said coated tablet is exposed to aqueous solutions.

3. The tablet of claim 1, wherein said insoluble therapeutically active agent is selected from the group consisting of acetaminophen, naproxen and indomethacin.

4. The tablet of claim 1, wherein said tablet core further comprises a second therapeutically active agent in a sufficient amount to render a therapeutic effect, said second therapeutically active agent being relatively soluble in water compared to said insoluble therapeutically active agent and being selected from the group consisting of antihistamines, analgesics, anti-inflammatory agents, gastro-intestinals, anti-emetics, anti-epileptics, vasodilators, anti-tussive agents, expectorants, anti-asthmatics, anti-spasmodics, hormones, diuretics, anti-hypotensives, bronchodilators, anti-inflammatory steroids, antivirals, antibiotics, antihemorrhoidals, hypnotics, psychotropics, antidiarrheals, mucolytics, sedatives, decongestants, laxatives, antacids, vitamins, and stimulants.

5. The tablet of claim 4, wherein said insoluble therapeutically active agent is acetaminophen, and said second therapeutically active agent is selected from the group consisting of hydromorphone, oxycodone, dihydrocodeine, codeine, dihydromorphine, morphine, buprenorphine, salts of any of the foregoing, and mixtures of any of the foregoing.

6. The tablet of claim 1, wherein said film coating comprises a plasticized pharmaceutically acceptable acrylic polymer.

7. The tablet of claim 1, wherein said film coating comprises plasticized ethylcellulose.

9. The tablet of claim 1, which releases said insoluble therapeutically active agent over a time period of about 24 hours when exposed to fluids in an environment of use.

10. The tablet of claim 5, wherein said insoluble therapeutically active agent is acetaminophen, and said second therapeutically active agent is codeine or oxycodone.

2. A method of treating, a patient with a dose of a pharmaceutical formulation containing an insoluble therapeutically active agent over an extended period of time, comprising

preparing an immediate release solid tablet core comprising a therapeutically active agent in an amount sufficient to render a therapeutic effect, the therapeutically active agent having a solubility of less than or equal to about 5 mg/ml:

coating said tablet core with a hydrophobic material selected from the group consisting of waxes, shellac, zein, fatty alcohols, hydrogenated vegetable oils, water insoluble celluloses, acrylic polymers and mixtures thereof, such that said formulation reproducibly releases said insoluble therapeutically active agent at a dissolution rate between 12.5% and 42.5% (by wt) released after 4 hours and between 55% and 85% (by wt) after 6 hours when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37°

C., and provides a duration of effect from about 8 to about 44 hours.

21. The method of claim 2, wherein said insoluble therapeutically active agent is acetaminophen,

further comprising incorporating into said tablet core an effective amount of a second therapeutically active agent selected from the group consisting of hydromorphone, oxycodone, dihydrocodeine, codcine, dihydromorphine, morphine, buprenorphine, salts of any of the foregoing, and mixtures of any of the foregoing.

8. A sustained release tablet for oral administration, comprising an immediate release tablet core including from about 300 mg to about 500 mg acetaminophen, and a therapeutically effective amount of an analgesic agent selected from the group consisting of hydromorphone, oxycodone, dihydrocodeine, codeine, dihydromorphine, morphine, buprenorphine, salts of any of the foregoing, and mixtures of any of the foregoing, said immediate release tablet core providing the dissolution of not less than 75% of the acetaminophen in 45 minutes when said tablet core is placed in 900 ml 0.1N hydrochloric acid, said tablet core being coated with a sufficient amount of a hydrophobic material selected from the group consisting of waxes, shellac, zein, fatty alcohols, hydrogenated vegetable oils, water insoluble celluloses, acrylic polymers and mixtures thereof such that said acetaminophen and said analgesic agent are released from the coated tablet over an extended period of time, and provide a duration of effect of from about 12 hours to about 24 hours.

22. The tablet of claim 8, wherein said coating comprises an aqueous dispersion of a plasticized pharmaceutically acceptable acrylic polymer cured at a temperature greater than the glass transition temperature of the aqueous dispersion of plasticized acrylic polymer until an endpoint is reached at which said cured coated tablet provides a stable dissolution profile, said endpoint being determined by comparing the dissolution profile of the coated tablet immediately after curing to the dissolution profile of the coated tablet after exposure to accelerated storage conditions of three months at a temperature from about 37°

C. to about 40°

C. and a relative humidity from about 75% to about 80%.

23. The tablet of claim 8, wherein said coating comprises an aqueous dispersion of plasticized ethylcellulose cured at a temperature greater than the glass transition temperature of the aqueous dispersion of plasticized ethylcellulose and at from about 60% to about 100% relative humidity until an endpoint is reached at which the coated tablet provides a stable dissolution profile, said endpoint being determined by comparing the dissolution profile of the tablet immediately after curing to the dissolution profile of the tablet after exposure to accelerated storage conditions of three months at a temperature from about 37°

C. to about 40°

C. and at a relative humidity from about 75% to about 80%.

24. The tablet of claim 8, wherein said analgesic agent comprises from about 5 mg to about 10 mg oxycodone.

25. The tablet of claim 8, wherein said analgesic agent comprises from about 15 to about 60 mg codeine phosphate.

11. A sustained release tablet for oral administration, comprising an immediate release tablet core including an insoluble therapeutically active agent having an aqueous solubility of less than or equal to about 5 mg/ml, said tablet core containing a sufficient amount of said therapeutically active drug to render a therapeutic effect, said tablet core coated with a sustained release film coating comprising a hydrophobic material selected from the group consisting of waxes, shellac, zein, fatty alcohols, hydrogenated vegetable oils, water insoluble celluloses, acrylic polymers and mixtures thereof permitting a dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm in 900 ml aqueous buffer, pH between about 1.6 and about 7.2, at 37°

C. between 12.5 and 42.5% (by wt) released after 1 hour, between 45 and 56% (by wt) released after 2 hours, between 45 and 75% (by wt) released after 4 hours and between 55 and 85% (by wt) released after 6 hours, and providing a duration of effect of from about 8 to about 24 hours.

12. The tablet of claim 11, wherein said film coating is sufficient to permit a sustained release of said insoluble therapeutically active agent sufficient to provide a duration of effect of from about 12 to about 24 hours.

13. The tablet of claim 11, wherein said insoluble therapeutically active agent is selected from the group consisting of acetaminophen, naproxen and indomethacin.

14. The tablet of claim 11, wherein said tablet core further comprises a second therapeutically active agent in a sufficient amount to render a therapeutic effect, said second therapeutically active agent being soluble in water relative to said insoluble therapeutically active agent and being selected from the group consisting of antihistamines, analgesics, anti-inflammatory agents, gastro-intestinals, anti-emetics, anti-epileptics, vasodilators, anti-tussive agents, expectorants, anti-asthmatics, antispasmodics, hormones, diuretics, anti-hypotensives, bronchodilators, anti-inflammatory steroids, antivirals, antibiotics, antihemorrhoidals, hypnotics, psychotropics, antidiarrheals, mucolytics, sedatives, decongestants, laxatives, antacids, vitamins, and stimulants.

15. The tablet of claim 14, wherein said insoluble therapeutically active agent is acetaminophen, and said second therapeutically active agent is selected from the group consisting of hydromorphone, oxycodone, dihydrocodeine, codeine, dihydromorphine, morphine, buprenorphine, salts of any of the foregoing, and mixtures of any of the foregoing.

16. The tablet of claim 15, comprising from about 300 mg to about 500 mg acetaminophen and from about 5 to about 10 mg oxycodone.

17. The tablet of claim 12, wherein said film coating comprises an aqueous dispersion of a plasticized acrylic polymer cured at a temperature greater than the glass transition temperature of the aqueous dispersion of said plasticized acrylic polymer until an endpoint is reached at which said cured coated tablet provides a stable dissolution, said endpoint being determined by comparing the dissolution profile of said coated tablet immediately after curing to the dissolution profile of said coated tablet after exposure to accelerated storage conditions of three months at a temperature from about 37°

C. to about 40°

C. and a relative humidity from about 75% to about 80%.

18. The tablet of claim 12, wherein said film coating comprises an aqueous dispersion of plasticized ethylcellulose cured at a temperature greater than the glass transition temperature of the aqueous dispersion of said plasticized ethylcellulose and at from about 60% to about 100% relative humidity until an endpoint is reached at which said cured coated tablet provides a stable dissolution profile, said endpoint being determined by comparing the dissolution profile of said coated tablet immediately after curing to the dissolution profile of said coated tablet after exposure to accelerated storage conditions of three months at a temperature from about 37°

C. to about 40°

C. and a relative humidity from about 75% to about 80%.

19. The tablet of claim 11, wherein said tablet core is coated with said hydrophobic material to a weight gain level from about 3 to about 20 percent.

20. The tablet of claim 15, wherein said second therapeutically active agent is selected from the group consisting of from about 5 mg to about 10 mg oxycodone, and from about 15 mg to about 60 mg codeine phosphate.